Últimas noticias sobre Getty Images Holdings (NYSE:GETY) Bolsa

Getty Images Holdings

Getty Images Holdings Inc is engaged in the core mission of bringing the world's creative and editorial visual content solutions to its customers to engage their audiences. the company has developed market enhancements across e-commerce, content subscriptions, user-generated content, diverse and inclusive content, and proprietary research alongside investment in its technology platform, which includes artificial intelligence and machine learning-driven search functionality and image editing and integrated APIs, to become a trusted industry leader in the visual content. Geographically the company operates in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, out of which a majority of its revenue is generated from the Americas.

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

GETY

SGMO

STNE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: IHS, HQY, GETY, SGMO y STNE.

5 acciones en el foco este martes: IHS, HQY, GETY, SGMO y STNE

CWCO

SAIC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: SAIC, GETY, CTM, CWCO y TSQ.

5 acciones en el foco este lunes: SAIC, GETY, CTM, CWCO y TSQ

Getty Images Holdings, Inc. Class A Common Stock

Getty Images Holdings Inc

Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $406.38, with a high estimate of $451.00 and a low estimate of $358.00. Observing a 4.37% increase, the current average has risen from the previous average price target of $389.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302869_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Cummins among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$375.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$451.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>David Leiker</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$407.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Adam Seiden</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$381.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$425.00</td>
<td>$424.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$430.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Michael Feniger</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$358.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$424.00</td>
<td>$369.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cummins. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cummins compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Cummins's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cummins's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CMI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cummins analyst ratings.</a>
<h2>Delving into Cummins's Background</h2>
Cummins is the top manufacturer of diesel engines used in commercial trucks, off-highway machinery, and railroad locomotives, in addition to standby and prime power generators. The company also sells powertrain components, which include transmissions, turbochargers, aftertreatment systems, and fuel systems. Cummins is in the unique position of competing with its primary customers, heavy-duty truck manufacturers, who make and aggressively market their own engines. Despite robust competition across all its segments and increasing government regulation of carbon emissions, Cummins has maintained its leadership position in the industry.
<h3>Unraveling the Financial Story of Cummins</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Negative Revenue Trend: Examining Cummins's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.12% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 4.95%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Cummins's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.06%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cummins's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.31%, the company showcases efficient use of assets and strong financial health.
Debt Management: Cummins's debt-to-equity ratio is below the industry average. With a ratio of 0.74, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Cummins: Insights From 8 Financial Analysts

During the last three months, 4 analysts shared their evaluations of Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.0, a high estimate of $45.00, and a low estimate of $39.00. A 5.08% drop is evident in the current average compared to the previous average price target of $44.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302855_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Atmus Filtration Techs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Atmus Filtration Techs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Atmus Filtration Techs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Atmus Filtration Techs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Atmus Filtration Techs's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ATMU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Atmus Filtration Techs analyst ratings.</a>
<h2>Unveiling the Story Behind Atmus Filtration Techs</h2>
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. It designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products for first-fit and aftermarket applications including air filters, fuel filters, fuel water separators, lube filters, hydraulic filters, coolants, fuel additives, and other filtration systems to original equipment manufacturers, dealers/distributors, and end-users.
<h3>Atmus Filtration Techs: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Atmus Filtration Techs displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 1.75%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Atmus Filtration Techs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.86%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Atmus Filtration Techs's ROE stands out, surpassing industry averages. With an impressive ROE of 17.88%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Atmus Filtration Techs's ROA excels beyond industry benchmarks, reaching 3.33%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 2.78, Atmus Filtration Techs faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATMU

Analyst Expectations For Atmus Filtration Techs's Future

Dividends

QCOM

Qualcomm Increases Quarterly Dividend From $0.85 To $0.89/Share

During the last three months, 7 analysts shared their evaluations of AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for AVITA Medical, presenting an average target of $22.0, a high estimate of $25.00, and a low estimate of $14.00. This current average has decreased by 4.35% from the previous average price target of $23.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302846_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of AVITA Medical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brooks O'Neil</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AVITA Medical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of AVITA Medical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AVITA Medical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RCEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AVITA Medical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind AVITA Medical</h2>
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
<h3>Key Indicators: AVITA Medical's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: AVITA Medical's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 29.67%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: AVITA Medical's net margin is impressive, surpassing industry averages. With a net margin of -62.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AVITA Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -138.57%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): AVITA Medical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -14.42%, the company may face hurdles in achieving optimal financial performance.
Debt Management: AVITA Medical's debt-to-equity ratio surpasses industry norms, standing at 10.22. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RCEL

What Analysts Are Saying About AVITA Medical Stock

Newell Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NYSE">NWL</a>) short percent of float has risen 4.37% since its last report. The company recently reported that it has 18.68 million shares sold short, which is 7.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Newell Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742302830_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Newell Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Newell Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Newell Brands's peer group average for short interest as a percentage of float is 6.67%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Newell Brands?

In the latest quarter, 6 analysts provided ratings for Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $181.67, a high estimate of $205.00, and a low estimate of $155.00. Highlighting a 7.12% decrease, the current average has fallen from the previous average price target of $195.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302831_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Repligen's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Markowitz</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$155.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Repligen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Repligen compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Repligen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Repligen's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RGEN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Repligen analyst ratings.</a>
<h2>All You Need to Know About Repligen</h2>
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
<h3>Repligen's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Repligen showcased positive performance, achieving a revenue growth rate of 0.56% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Repligen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -20.21% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Repligen's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.7%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Repligen's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Repligen's debt-to-equity ratio is below the industry average. With a ratio of 0.35, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGEN

Demystifying Repligen: Insights From 6 Analyst Reviews

First Citizens BancShares's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NYSE">FCNCA</a>) short percent of float has risen 22.58% since its last report. The company recently reported that it has 323 thousand shares sold short, which is 3.04% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>First Citizens BancShares Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742302825_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First Citizens BancShares has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing First Citizens BancShares's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, First Citizens BancShares's peer group average for short interest as a percentage of float is 1.06%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FCNCA

How Do Investors Really Feel About First Citizens BancShares?

4 analysts have expressed a variety of opinions on Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $139.0, with a high estimate of $149.00 and a low estimate of $120.00. This current average represents a 6.87% decrease from the previous average price target of $149.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302823_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Science Applications Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$148.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$120.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Matthew Akers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$154.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Science Applications Intl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Science Applications Intl compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Science Applications Intl's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Science Applications Intl's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAIC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Science Applications Intl analyst ratings.</a>
<h2>All You Need to Know About Science Applications Intl</h2>
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, the company offers engineering, systems integration, and information technology for large government projects and a broad range of services with an emphasis on higher-end technology services. The company's end-to-end enterprise IT offerings span the entire spectrum of customers' IT infrastructure.
<h3>Unraveling the Financial Story of Science Applications Intl</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Science Applications Intl's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 4.27%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Science Applications Intl's net margin is impressive, surpassing industry averages. With a net margin of 5.36%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Science Applications Intl's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 6.55%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.01%, the company showcases effective utilization of assets.
Debt Management: Science Applications Intl's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.46.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Science Applications Intl Through The Eyes Of 4 Analysts

Ulta Beauty's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NYSE">ULTA</a>) short percent of float has fallen 13.4% since its last report. The company recently reported that it has 2.36 million shares sold short, which is 6.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.4 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Ulta Beauty Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742302819_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ulta Beauty has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ulta Beauty's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Ulta Beauty's peer group average for short interest as a percentage of float is 13.18%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ULTA

How Do Investors Really Feel About Ulta Beauty?

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on ESAB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESAB#NYSE">ESAB</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $132.25, with a high estimate of $140.00 and a low estimate of $125.00. No alteration is observed as the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1742302815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive ESAB is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$125.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$131.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ESAB. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ESAB compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of ESAB's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ESAB's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ESAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ESAB analyst ratings.</a>
<h2>Get to Know ESAB Better</h2>
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
<h3>Financial Insights: ESAB</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: ESAB's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -2.7%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: ESAB's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 8.01%, the company may face hurdles in effective cost management.
Return on Equity (ROE): ESAB's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): ESAB's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.32%, the company may face hurdles in achieving optimal financial returns.
Debt Management: ESAB's debt-to-equity ratio stands notably higher than the industry average, reaching 0.66. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ESAB

4 Analysts Have This To Say About ESAB

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Overweight to Overweight.

Reiteration

ACRS

Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeuticsto Overweight

Soluna Holdings, Inc. ("Soluna" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications, including Bitcoin mining and AI, announced today that it has successfully closed a $5 million loan facility with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.galaxy.com%2F&amp;esheet=54225522&amp;newsitemid=20250318203334&amp;lan=en-US&amp;anchor=Galaxy+Digital&amp;index=1&amp;md5=67bec3983b299c97a77f173cf1716e82">Galaxy Digital</a> ("Galaxy") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GLXY#TSX">GLXY</a>), a financial services and investment management innovator in the digital asset and blockchain technology sectors.
The loan will have a five-year term. It is secured, with limited recourse to the parent company—highlighting the strength of project-level standalone cash flows and the ability to attract institutional financing. The Company has the right to prepay the loan, in whole or in part, at any time, subject to certain requirements defined by the Loan Agreement.

Financing

SLNH

TSX:GLXY

Soluna Announces It Has Closed A $5M Loan Facility With Galaxy Digital

Management

Gannett Appoints Trisha Gosser As CFO; Douglas Horne To Step Down As CFO, Both Effective March 18, 2025

COST CLIMBS OVER 17 POINTS AFTER TRADEPULSE ALERT
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="546" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17225807/Screen-Shot-2025-03-17-at-6.53.12-PM-1024x546.png" alt="" class="wp-image-8145" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17225807/Screen-Shot-2025-03-17-at-6.53.12-PM-1024x546.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17225807/Screen-Shot-2025-03-17-at-6.53.12-PM-300x160.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17225807/Screen-Shot-2025-03-17-at-6.53.12-PM-768x410.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/17225807/Screen-Shot-2025-03-17-at-6.53.12-PM.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Costco, Inc. (COST) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:05 AM on March 17th, a significant trading signal occurred for Costco, Inc. (COST) as it demonstrated a Power Inflow at a price of $905.74. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Costco&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Costco&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for COST, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trade alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The price at the time of the Power Inflow was $905.74. The returns on the High price ($923.39) and Close price ($916.61) after the Power Inflow were respectively 1.9% and 1.2%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Performance is Not Indicative of Future Results

Equities

Technicals

Opinion

Signals

COST

Costco Shares Rise 1.9% After Key Signal

Apple Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) latest shipment data from China paints a concerning picture: foreign-branded phone shipments — a strong indicator of iPhone sales — dropped 21% <a href="https://www.benzinga.com/tech">year-over-year in January</a>.
That&#8217;s a sharp reversal from December's slight growth. 
While the decline adds to ongoing concerns over Apple's market position in China, a closer look at the numbers suggests the worst may be behind the company.
In a note shared Monday, Goldman Sachs analyst Michael Ng highlighted the latest data from the China Academy of Information and Communications Technology. Overall mobile phone shipments in China fell 14% year-over-year to 27.2 million units in January, the biggest decline since September's 24% drop.
See Also: <a href="https://www.benzinga.com/25/03/44372544/us-stocks-swing-as-futures-turn-flat-ahead-of-fomc-meeting-analysts-say-only-certainty-is-that-things-will-remain-uncertain-for-the-time-being">US Futures Show Caution Among Investors Ahead Of FOMC Meeting</a>
<h3 class="wp-block-heading">Is Apple Still Losing Ground in China?</h3>
The numbers reflect a clear trend: Apple's sales in China have been under pressure for months. From September to November 2024, foreign-branded phone shipments in the country collapsed by more than 40% annually each month, indicating that Apple was losing share to domestic competitors such as Huawei Technologies Co. and Xiaomi Corp. (OTCPK: XIACY)
Yet, the January figures offer a silver lining. While still negative on a yearly basis, the 21% year-over-year decline represents an improvement over the 40%-47% plunges seen in previous months.
Goldman Sachs notes that December and January results &#8220;may have benefited from inventory build&#8221; ahead of the implementation of national consumer smartphone subsidies on Jan. 20.
Additionally, foreign-branded shipments rose 17% month-over-month from December, suggesting some stabilization—though still below the typical seasonal jump of 51% seen in past years.
Foreign-branded phones held a 16% market share, up from 11% in December 2024, though still below the historical 17% in January 2024 and 48% in January 2023.
<h3 class="wp-block-heading">Goldman Sachs Holds &#8216;Buy&#8217; Rating, Keeps $294 Price Target On AAPL</h3>
Despite the weak shipment data, Goldman Sachs reaffirmed its &#8220;Buy&#8221; rating on AAPL with a 12-month price target of $294, implying a 37.7% upside from its latest closing price of $213.49. The valuation is based on 33x projected earnings for the next 12 months plus one year.
Apple shares were down 0.1% in premarket trading on Tuesday, reflecting cautious sentiment around the data.
The Cupertino-based tech giant is down 14.5% year-to-date, on track for the worst quarter since early 2022.
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44367075/chinese-stocks-poised-for-best-quarter-vs-sp-500-since-2007-as-investors-bet-on-policy-turnaround"> Chinese Stocks Poised For Best Quarter Vs. S&amp;P 500 Since 2007 As Investors Bet On Policy Turnaround</a></li>
</ul>
Image: Shutterstock

Asia

Large Cap

Tech

AAPL

XIACY

Apple iPhone Shipments In China Drop 21% In January, Goldman Sachs Remains Bullish

Macro Economic Events

Econ #s

Economics

USA Redbook (YoY) 5.2% Vs 5.7% Prior

<a href="https://www.globenewswire.com/Tracker?data=P1_GaCrD_zLP01GOSEaEm30A-AKN39-NgCg1JmdVYmhXKc2elzXDogmaFFygzI4Ytlr09OT90EHvyEi7Cow7ltcfgi6DQzpPRp7R1VdTVCA=">Vincerx Pharma, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) today announced that it has entered into a non-binding letter of intent ("LOI") with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx.
Under the proposed terms, a subsidiary of Vincerx would merge into QumulusAI, with QumulusAI stockholders receiving shares of Vincerx common stock. Additionally, QumulusAI options, warrants, and other rights would be converted into options, warrants, and rights to acquire Vincerx common stock. The exchange ratio is intended to result in QumulusAI equity holders owning approximately 95% of the combined company, while Vincerx equity holders would own approximately 5%. The proposed transaction assumes a value for QumulusAI of approximately $285 million and a value for Vincerx of approximately $15 million, assuming zero cash (net of liabilities) at closing. As part of the transaction, to the extent requested by Vincerx, QumulusAI or its designees will invest up to $1.5 million in the equity of Vincerx prior to closing.

Contracts

VINC

Vincerx Pharma Enters Non-Binding LOI With QumulusAI For Reverse Merger; QumulusAI To Own 95% Of Combined Entity Valued At $285M, Vincerx At $15M; QumulusAI Or Its Designees Will Invest Up To $1.5M In The Equity Of Vincerx Prior To Closing

On Monday, Nanobiotix SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV, a Johnson &amp; Johnson company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), as part of <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">its financial strategy</a>.
The revision relieves Nanobiotix of funding obligations for its pivotal NANORAY-312 Phase 3 trial while modifying certain <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44364428/nanobiotix-strengthens-financial-position-through-amendment-of-global-licensing-agreement-for-jnj-" rel="noreferrer noopener">future milestone payments</a>.
The company expects the changes to bolster its financial stability and extend its cash runway.
Under the revised agreement, Johnson &amp; Johnson will assume nearly all remaining costs for NANORAY-312 through trial completion, with Nanobiotix covering only a small portion.
Also Read: <a href="https://www.benzinga.com/markets/forex/25/03/44372206/asia-and-europe-markets-gains-gold-makes-new-high-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">Asia And Europe Markets Gains, Gold Makes New High &#8211; Global Markets Today While US Slept</a>
This shift significantly reduces Nanobiotix's financial burden and allows the company to focus on advancing its clinical pipeline.
The overall deal value has been adjusted from approximately $2.7 billion to $2.6 billion, with a $105 million reduction in potential future milestone payments.
However, Nanobiotix remains eligible for substantial success-based payments, including up to $1.77 billion in development, regulatory and sales milestones for its first programs, such as cisplatin-ineligible head and neck cancer and unresectable stage 3 non-small cell lung cancer.
Additionally, Johnson &amp; Johnson may develop up to five new indications at its discretion, potentially adding another $650 million in milestone payments.
Nanobiotix also retains eligibility for $165 million in milestone payments across China, South Korea, Singapore and Thailand. Furthermore, for each new indication developed under Nanobiotix's alignment with Johnson &amp; Johnson, the company could earn up to $220 million in additional milestone payments. Tiered royalties in the low double-digit range, from the low teens to low 20s, remain unchanged.
Financially, the amended agreement extends Nanobiotix's cash runway to mid-2026, with efforts underway to secure additional financing—preferably non-dilutive—to extend it further into 2027.
The company also expects a significant reduction in operational cash burn, as the NANORAY-312 trial previously accounted for a major portion of its expenses.
Price Action: NBTX stock is up 4.48% at $3.50 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44372525/finvolution-reports-strong-q4-eyes-50-revenue-from-international-markets-by-2030-more" target="_blank" rel="noreferrer noopener">FinVolution Reports Strong Q4, Eyes 50% Revenue From International Markets By 2030 &amp; More</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

NBTX

Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden

Scotiabank analyst Jonathan Goldman maintains TerraVest Industries (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TVK#TSX">TVK</a>) with a Sector Outperform and raises the price target from C$126 to C$140.

Price Target

TSX:TVK

Scotiabank Maintains Sector Outperform on TerraVest Industries, Raises Price Target to C$140

As of March 18, 2025, two stocks in the communication services sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>)</h3>
<ul>
<li>On Feb. 4, Electronic Arts announced preliminary financial results for its third quarter ended Dec. 31, 2024. &#8220;The record success of our EA SPORTS FC 25 Team of the Year event demonstrates our creative teams&#8217; ability to adapt, innovate, and execute at scale,&#8221; said Andrew Wilson, CEO of Electronic Arts. &#8220;As we build on this momentum across EA, we are confident in a return to growth in FY26 and beyond as we bring our next wave of iconic entertainment to players and fans worldwide.&#8221; The company's stock gained around 11% over the past month and has a <a href="https://www.benzinga.com/quote/EA">52-week high of $168.50</a>.</li>
<li>RSI Value: 70.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>EA Price Action: Shares of Electronic Arts gained 3.1% to close at $142.90 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)</h3>
<ul>
<li>On March 12, Baidu announced completion of CNY10 billion offering of CNY-denominated senior notes. The company's stock gained around 13% over the past month and <a href="https://www.benzinga.com/quote/BIDU">has a 52-week high</a> of $116.25.</li>
<li>RSI Value: 74</li>
<li>BIDU Price Action: Shares of Baidu closed at $102.27 on Monday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>

BIDU

Top 2 Tech And Telcom Stocks That May Keep You Up At Night In March

Legal

Press Releases

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, NARI, SSY on Behalf of Shareholders

Kuehn Law Encourages VINC, NEUE, GETY, and CLBR Investors to Contact Law Firm

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates GETY, CLBR, VINC, NEUE on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TURN, DFS, GETY on Behalf of Shareholders

Getty Images and Verizon to Award $20,000 Grant to Champion Disability Representation in the Workplace

Getty Images Holdings, Inc. Announces Comprehensive Refinancing of Approximately $1.042 Billion Existing Term Loans

Getty Images to Release Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

Sports

Getty Images and UEFA Renew Multi-Year Agreement

Getty Images Signs Multi-Year Photography Partnership with the National Women's Soccer League

Getty Images Reports Fourth Quarter and Full Year 2024 Results

CLBR

NARI

NEUE

TURN

Angi

Bumble

Cars.com

Trump Media & Technology Group Corp. - Warrants

Trump Media & Technology

EverQuote

FuboTV

Nextdoor Holdings, Inc. Class A Common Stock

Nextdoor Holdings

MediaAlpha

Hello Group Inc. - American Depositary Shares

Hello Gr

Outbrain

QuinStreet

Shutterstock

Taboola.com

Tripadvisor

TrueCar

trivago N.V. - American Depositary Shares

trivago

Travelzoo

Vimeo

Vtex

WEBTOON Entertainment Inc. - Common stock

Webtoon Entertainment

Yalla Group Limited American Depositary Shares, each representing one Class A Ordinary Share

Yalla Group

Yelp

Ziff Davis

Zhihu Inc. American Depositary Shares, each representing three (3) Class A Ordinary Shares

Comments

Getty Images Holdings

Noticias

Últimas noticias sobre Getty Images Holdings (NYSE:GETY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL